PURPOSE: This is a phase II, single-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treated with adjuvant interferon-based chemoradiation followed by gemcitabine. The primary end point was 2-year overall survival, with secondary endpoints being 2-year disease-free survival, and the frequency of grade 3 or 4 toxicity. PATIENTS AND METHODS: From April 2002 to September 2005, 53 patients with adenocarcinoma of the pancreas underwent curative resection at a single institution, and subsequently received interferon- and gemcitabine-based adjuvant therapy consisting of external-beam irradiation at a dose of 5040 cGy (25 fractions per 5 weeks) and simultaneous 3-drug chemotherapy consisting of (1) continuous infusion 5-fluorouracil (175 mg/m2); (2) weekly intravenous bolus cisplatin (25 mg/m2); and (3) interferon-alpha (3 million units subcutaneously 3 times per week) during the 6 weeks of radiation. This was followed by two 4-week courses of weekly intravenous infusion of gemcitabine (1000 mg/m2, 3 of 4 weeks). RESULTS: Median follow-up is 38 months. Seventy-seven percent of patients had node-positive disease. Sixteen patients (30%) failed to complete adjuvant therapy, due to disease progression (7 patients), toxicity (7 patients), and consent withdrawal (2 patients). No patients completed planned therapy without dose modification. Median overall survival was 25 months (confidence interval [CI] = 21.5-48.5 months). Actuarial overall survival for the 1-, 2- and 3-year periods were 75% (CI = 61-85%), 56% (CI = 41-69%), and 41% (26-55%), respectively. CONCLUSIONS: This phase II trial demonstrated increased patient survival compared with historical controls, and equivalent survival compared with the regimen combining interferon-alpha with 5-fluorouracil-based chemoradiation. Despite these encouraging results, significant concerns regarding dose- and treatment-limiting toxicities remain.
PURPOSE: This is a phase II, single-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treated with adjuvant interferon-based chemoradiation followed by gemcitabine. The primary end point was 2-year overall survival, with secondary endpoints being 2-year disease-free survival, and the frequency of grade 3 or 4 toxicity. PATIENTS AND METHODS: From April 2002 to September 2005, 53 patients with adenocarcinoma of the pancreas underwent curative resection at a single institution, and subsequently received interferon- and gemcitabine-based adjuvant therapy consisting of external-beam irradiation at a dose of 5040 cGy (25 fractions per 5 weeks) and simultaneous 3-drug chemotherapy consisting of (1) continuous infusion 5-fluorouracil (175 mg/m2); (2) weekly intravenous bolus cisplatin (25 mg/m2); and (3) interferon-alpha (3 million units subcutaneously 3 times per week) during the 6 weeks of radiation. This was followed by two 4-week courses of weekly intravenous infusion of gemcitabine (1000 mg/m2, 3 of 4 weeks). RESULTS: Median follow-up is 38 months. Seventy-seven percent of patients had node-positive disease. Sixteen patients (30%) failed to complete adjuvant therapy, due to disease progression (7 patients), toxicity (7 patients), and consent withdrawal (2 patients). No patients completed planned therapy without dose modification. Median overall survival was 25 months (confidence interval [CI] = 21.5-48.5 months). Actuarial overall survival for the 1-, 2- and 3-year periods were 75% (CI = 61-85%), 56% (CI = 41-69%), and 41% (26-55%), respectively. CONCLUSIONS: This phase II trial demonstrated increased patient survival compared with historical controls, and equivalent survival compared with the regimen combining interferon-alpha with 5-fluorouracil-based chemoradiation. Despite these encouraging results, significant concerns regarding dose- and treatment-limiting toxicities remain.
Authors: Dirk Spitzer; Peter O Simon; Hiroyuki Kashiwagi; Jinbin Xu; Chenbo Zeng; Suwanna Vangveravong; Dong Zhou; Katherine Chang; Jonathan E McDunn; John R Hornick; Peter Goedegebuure; Richard S Hotchkiss; Robert H Mach; William G Hawkins Journal: Cancer Res Date: 2011-11-07 Impact factor: 12.701
Authors: V J Picozzi; R A Abrams; P A Decker; W Traverso; E M O'Reilly; E Greeno; R C Martin; L S Wilfong; M L Rothenberg; M C Posner; P W T Pisters Journal: Ann Oncol Date: 2010-07-29 Impact factor: 32.976
Authors: Matthew R Porembka; Jonathan B Mitchem; Brian A Belt; Chyi-Song Hsieh; Hyang-Mi Lee; John Herndon; William E Gillanders; David C Linehan; Peter Goedegebuure Journal: Cancer Immunol Immunother Date: 2012-01-04 Impact factor: 6.968
Authors: Jason R Baird; Arta M Monjazeb; Omid Shah; Heather McGee; William J Murphy; Marka R Crittenden; Michael J Gough Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-19 Impact factor: 7.038
Authors: Leonard Armstrong; Julia Davydova; Eric Brown; Joohee Han; Masato Yamamoto; Selwyn M Vickers Journal: Surgery Date: 2012-04-11 Impact factor: 3.982
Authors: Kerri A Ohman; Jingxia Liu; David C Linehan; Marcus C Tan; Benjamin R Tan; Ryan C Fields; Steven M Strasberg; William G Hawkins Journal: HPB (Oxford) Date: 2017-02-03 Impact factor: 3.647
Authors: May Cho; Andrea Wang-Gillam; Robert Myerson; Feng Gao; Steven Strasberg; Joel Picus; Steven Sorscher; Chloe Fournier; Gayathri Nagaraj; Parag Parikh; Rama Suresh; David Linehan; Benjamin R Tan Journal: HPB (Oxford) Date: 2015-03-20 Impact factor: 3.647
Authors: Eric H Jensen; Leonard Armstrong; Chung Lee; Todd M Tuttle; Selwyn M Vickers; Timothy Sielaff; Edward W Greeno Journal: HPB (Oxford) Date: 2013-03-19 Impact factor: 3.647